10x Genomics Raises 2026 Revenue Outlook
The life sciences company now expects $625 million to $635 million in 2026 revenue, up from its previous range, as spatial biology demand grows.
Updated on Nov. 7, 2026 in Biotech
10x Genomics raised its 2026 revenue outlook to $625 million to $635 million, up from $610 million to $630 million. The company also lifted its year-end target for Atera instrument shipments to approximately 50 units from approximately 40.
Why it matters
The revision reflects third-quarter performance, stronger-than-anticipated spatial consumables sales, and higher expected Atera demand. It signals momentum for U.S. spatial biology tools used in biomedical research.
Third-quarter revenue reached $150.7 million, up 1% from $149 million a year earlier, and the updated 2026 outlook implies 4% to 6% growth over 2025 after excluding one-time licensing and royalty income from patent settlements. The company has not addressed whether the 50-instrument Atera target depends on consumables adoption.
The players
10x Genomics
A life sciences company based in California that develops single-cell and spatial biology tools used in biomedical research.
The details
10x Genomics began global commercial shipments of Atera in September, after introducing the in situ spatial biology platform in April. The platform is designed for whole-transcriptome analysis with single-cell sensitivity. The revised outlook excludes nonrecurring license and royalty revenue tied to patent litigation settlements in both years.
Timeline
April 2026: Atera introduced as an in situ spatial biology platform.
September 2026: Global commercial shipments of Atera began.
September 30, 2026: Third-quarter period ended with $150.7 million in revenue.
Year-end 2026: Target of approximately 50 Atera instrument shipments.
The Tech Race
The revised outlook reflects the commercial rollout of Atera, a spatial biology platform that began global shipments only in September 2026. Its ramp against the company's existing single-cell tools will show whether spatial analysis can add meaningful growth to the company's U.S. research-instrument business.
For researchers and labs using spatial biology tools, the Atera rollout expands options for whole-transcriptome analysis within tissue samples. Institutions evaluating new platforms may see added pricing and availability details as shipments scale through year-end.
The takeaway
Companies in spatial biology are shifting from research novelty toward recurring consumables revenue, which can make quarterly results a clearer signal of adoption. Readers tracking life sciences tools should watch whether shipment targets translate into sustained consumables sales.
Further reading
For related coverage, explore more Biotech developments shaping life sciences research.
Source note: This article includes information reported by TokenPost.
